Identifying patient subgroups that are most likely to benefit from medications used to treat alcohol use disorder
确定最有可能从用于治疗酒精使用障碍的药物中受益的患者亚组
基本信息
- 批准号:10555243
- 负责人:
- 金额:$ 17.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-01 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AbstinenceAdoptionAffectAlcohol consumptionAmbulatory CareAwardCharacteristicsChronic DiseaseClinical TrialsCompetenceConduct Clinical TrialsDataData SourcesDatabasesDevelopment PlansDiseaseEffectivenessEnvironmentEpidemiologyEvaluationExclusion CriteriaFrequenciesGoalsHealthHealth PersonnelHealth ServicesHeavy DrinkingIndividualInterventionLabelLiteratureMeasuresMedicalMedicareMedicineMentored Research Scientist Development AwardMentorsMentorshipMethodologyMethodsNational Institute on Alcohol Abuse and AlcoholismObservational StudyOutcomeOutcome MeasurePatientsPersonsPharmaceutical PreparationsPharmacoepidemiologyPrivatizationPublic HealthPublic Health SchoolsPublishingRecommendationResearchResearch MethodologyResearch PersonnelRiskSample SizeSamplingStatistical Data InterpretationStrategic PlanningSubgroupTechniquesTestingTimeTrainingUncertaintyUnited StatesUnited States Food and Drug AdministrationWorkWorld Health Organizationaddictionalcohol responsealcohol use disordercare outcomescareer developmentclinical careclinical decision-makingclinical practicedrinkingevidence basehospital careimprovedinnovationmultiple data sourcesnovelpatient subsetspersonalized decisionprofessorprogramspsychosocialstatistical learning
项目摘要
PROJECT SUMMARY/ABSTRACT
The objective of this K01 award is to provide Dr. Joshua Wallach, an Assistant Professor of Epidemiology at
the Yale School of Public Health, with the protected time necessary to become an independent expert in
synthesizing, evaluating, and establishing the best evidence to inform clinical practice in the field of alcohol use
disorder (AUD). Although AUD is a common and morbid disease, for which medication treatment is available,
uncertainties about whether and for whom treatments work may be causing AUD medication underutilization.
To advance the evidence base to support AUD medication treatment, research is needed to identify patient
subgroups that are most likely to benefit from each medication used to treat AUD. However, traditional
subgroup analyses often consider only one patient characteristic at a time and are conducted in small clinical
trials with strict exclusion criteria, short durations, and outcomes that may not reflect how patients feel or
function. This proposed K01 will address these limitations by conducting subgroup analyses using multiple
data sources, outcomes, and analytical techniques. In Aim 1, Dr. Wallach will identify and assess the validity of
already published subgroup analyses to establish promising patient subgroups that are most likely to benefit
from each medication used to treat AUD. In Aim 2, existing data from the largest AUD trial in the US (the
COMBINE study) will be used to (a) corroborate promising patient subgroup differences identified in Aim 1 and
(b) explore new differences between patient subgroups, using multiple methods (i.e. traditional and statistical
learning, which can consider multiple characteristics) and outcome measures (abstinence, heavy drinking, and
2-shift reduction in World Health Organization drinking levels). In Aim 3, claims data from OptumLabs, a
database of over 150 million privately insured and Medicare Advantage enrollees, will be used to determine
whether the same, similar, or new differences between patient subgroups are observed in real-world settings
when hospital and ambulatory care outcomes are considered. These aims will clarify uncertainties among
patients and clinicians regarding the adoption of AUD medications, which can decrease the public health
burden associated with AUD. To support these aims, Dr. Wallach’s career development plan will include
training in: (1) AUD medications and addiction medicine, (2) novel statistical learning techniques that can be
used to inform individualized clinical decision making, and (3) pharmacoepidemiology and observational
research methods for real-world medical product evaluation. The candidate has identified an interdisciplinary
team of mentors and advisors, including co-primary mentors Dr. Joseph Ross, a health services researcher
and administrative data expert, and Dr. Stephanie O’Malley, an AUD treatment and addiction medicine expert.
The Yale Schools of Public Health and Medicine provide the ideal environment for career development. This
K01 will prepare Dr. Wallach for an R01 submission, and will facilitate his long-term goal of developing an
innovative research program combining meta-research and real-world evaluation to improve AUD clinical care.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshua David Wallach其他文献
Joshua David Wallach的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshua David Wallach', 18)}}的其他基金
Identifying Patient Subgroups That Are Most Likely To Benefit From Medications Used To Treat Alcohol Use Disorder
确定最有可能从用于治疗酒精使用障碍的药物中受益的患者亚组
- 批准号:
10334521 - 财政年份:2021
- 资助金额:
$ 17.51万 - 项目类别:
Identifying patient subgroups that are most likely to benefit from medications used to treat alcohol use disorder
确定最有可能从用于治疗酒精使用障碍的药物中受益的患者亚组
- 批准号:
10698725 - 财政年份:2021
- 资助金额:
$ 17.51万 - 项目类别:
相似海外基金
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 17.51万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 17.51万 - 项目类别:
Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 17.51万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 17.51万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 17.51万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 17.51万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 17.51万 - 项目类别:
Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 17.51万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 17.51万 - 项目类别:
EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 17.51万 - 项目类别:
Standard Grant